PL2187742T3 - Pochodne (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylofenylo)-6-(hydroksymetylo) tetrahydro-2h-pirano-3,4,5-triolu do stosowania w leczeniu cukrzycy - Google Patents

Pochodne (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylofenylo)-6-(hydroksymetylo) tetrahydro-2h-pirano-3,4,5-triolu do stosowania w leczeniu cukrzycy

Info

Publication number
PL2187742T3
PL2187742T3 PL08798514T PL08798514T PL2187742T3 PL 2187742 T3 PL2187742 T3 PL 2187742T3 PL 08798514 T PL08798514 T PL 08798514T PL 08798514 T PL08798514 T PL 08798514T PL 2187742 T3 PL2187742 T3 PL 2187742T3
Authority
PL
Poland
Prior art keywords
benzylphenyl
pyran
tetrahydro
hydroxymethyl
diabetes
Prior art date
Application number
PL08798514T
Other languages
English (en)
Inventor
Yanli Song
Yuanwei Chen
Huawei Cheng
Shengbin Li
Yuelin Wu
Yan Feng
Binhua Lv
Baihua Xu
Brian Seed
Michael J. Hadd
Jiyan Du
Congna Wang
Jacques Y. Roberge
Original Assignee
Theracos Sub, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theracos Sub, Llc filed Critical Theracos Sub, Llc
Publication of PL2187742T3 publication Critical patent/PL2187742T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL08798514T 2007-08-23 2008-08-22 Pochodne (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylofenylo)-6-(hydroksymetylo) tetrahydro-2h-pirano-3,4,5-triolu do stosowania w leczeniu cukrzycy PL2187742T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95762507P 2007-08-23 2007-08-23
PCT/US2008/074058 WO2009026537A1 (en) 2007-08-23 2008-08-22 Benzylbenzene derivatives and methods of use
EP08798514.9A EP2187742B1 (en) 2007-08-23 2008-08-22 (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol derivatives for use in the treatment of diabetes

Publications (1)

Publication Number Publication Date
PL2187742T3 true PL2187742T3 (pl) 2018-06-29

Family

ID=40378694

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08798514T PL2187742T3 (pl) 2007-08-23 2008-08-22 Pochodne (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylofenylo)-6-(hydroksymetylo) tetrahydro-2h-pirano-3,4,5-triolu do stosowania w leczeniu cukrzycy

Country Status (30)

Country Link
US (4) US7838499B2 (pl)
EP (2) EP3318562A3 (pl)
JP (1) JP4809931B2 (pl)
KR (1) KR101107425B1 (pl)
CN (1) CN101790311B (pl)
AR (2) AR068016A1 (pl)
AU (1) AU2008288770B2 (pl)
BR (1) BRPI0815708B8 (pl)
CA (1) CA2697349C (pl)
CY (1) CY1119810T1 (pl)
DK (1) DK2187742T3 (pl)
ES (1) ES2654894T3 (pl)
HK (1) HK1254895A1 (pl)
HR (1) HRP20180127T1 (pl)
HU (1) HUE035947T2 (pl)
IL (1) IL203915A (pl)
LT (1) LT2187742T (pl)
MX (1) MX2010002027A (pl)
NO (1) NO2187742T3 (pl)
NZ (1) NZ583369A (pl)
PL (1) PL2187742T3 (pl)
PT (1) PT2187742T (pl)
RS (1) RS56822B1 (pl)
RU (1) RU2497526C2 (pl)
SG (1) SG188800A1 (pl)
SI (1) SI2187742T1 (pl)
TW (1) TWI434691B (pl)
UA (1) UA99924C2 (pl)
WO (1) WO2009026537A1 (pl)
ZA (1) ZA201001051B (pl)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2187742T (pt) 2007-08-23 2018-01-04 Theracos Sub Llc Derivados de (2s,3r,4r,5s,6r)-2-(4-cloro-3-benzilfenil)-6-(hidroximetil)tetrahidro-2h-piran-3,4,5-triol para utilização no tratamento da diabetes
UA105480C2 (uk) 2007-09-10 2014-05-26 Янссен Фармацевтика Н.В. Спосіб одержання сполук, які застосовують як інгібітори натрійзалежного переносника глюкози
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
JP6071198B2 (ja) 2008-07-15 2017-02-01 テラコス，インコーポレーテッド 重水素化ベンジルベンゼン誘導体及び使用方法
AU2014201286B2 (en) * 2008-08-22 2015-07-02 Theracosbio, Llc Processes for the preparation of SGLT2 inhibitors
PT2324002T (pt) * 2008-08-22 2016-11-09 Theracos Sub Llc Processos para a preparação de inibidores de sglt2
MY155418A (en) 2008-08-28 2015-10-15 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
EP2367554A4 (en) * 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid reflux inhibitor for the treatment of obesity and diabetes
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CN102482250B (zh) 2009-07-10 2014-11-19 詹森药业有限公司 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的结晶方法
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
AU2010310956B2 (en) 2009-11-02 2014-05-08 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
AR079438A1 (es) 2009-12-09 2012-01-25 Panacea Biotec Ltd Derivados de azucar, composiciones farmaceuticas y sus usos
CN102134226B (zh) * 2010-01-26 2013-06-12 天津药物研究院 一类苯基c-葡萄糖苷衍生物、其制备方法和用途
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102234287B (zh) 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 硝基咪唑类化合物、其制备方法和用途
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN102372722A (zh) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
GB201101959D0 (en) 2011-02-04 2011-03-23 Univ Nottingham Novel ether linked compoundsand improved treatments for cardiac and cardiovascular disease
CN102643256B (zh) * 2011-02-18 2014-12-24 上海璎黎科技有限公司 一种芳基糖苷类化合物及其制备方法和应用
CN102675378A (zh) * 2011-03-09 2012-09-19 天津药物研究院 一类含环丙烷结构的c-葡萄糖苷衍生物、其制备方法和用途
JP5973551B2 (ja) 2011-04-13 2016-08-23 ヤンセン ファーマシューティカ エヌ．ベー． Ｓｇｌｔ２の阻害物質として有用な化合物の調製プロセス
CN102757415B (zh) * 2011-04-25 2015-07-29 北京普禄德医药科技有限公司 一种钠依赖性葡萄糖转运蛋白抑制剂及其制备方法和用途
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
CN102875503B (zh) * 2011-06-25 2016-05-25 山东轩竹医药科技有限公司 C-糖苷衍生物
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013038429A2 (en) 2011-09-13 2013-03-21 Panacea Biotec Ltd. Novel sglt inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20130109671A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Pediatric Cholestatic Liver Diseases
SG10201903512SA (en) 2011-10-28 2019-05-30 Lumena Pharmaceuticals Inc Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
WO2013090550A1 (en) * 2011-12-15 2013-06-20 National Health Research Institutes Novel glycoside compounds
WO2013152476A1 (en) * 2012-04-10 2013-10-17 Theracos, Inc. Process for the preparation of benzylbenzene sglt2 inhibitors
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
CA2891773C (en) 2012-11-20 2021-01-19 Lexicon Pharmaceuticals, Inc. Inhibitors of sodium glucose cotransporter 1
CN103910769B (zh) 2012-12-31 2018-10-02 上海璎黎药业有限公司 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2015043511A1 (en) 2013-09-27 2015-04-02 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivatives and their uses in medicine
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
US9315438B2 (en) 2014-01-03 2016-04-19 Xuanzhu Pharma Co., Ltd Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
CN104031098A (zh) * 2014-06-21 2014-09-10 李友香 降糖药物
CN104017031A (zh) * 2014-06-21 2014-09-03 李友香 降血糖药物和组合物
CN104086379B (zh) * 2014-07-29 2015-08-12 安徽联创生物医药股份有限公司 达格列净中间体的合成方法
JP2016060698A (ja) * 2014-09-16 2016-04-25 本田技研工業株式会社 １，２−ビス（２，２−ジフルオロエトキシ）エタンおよびその製造方法
US9305155B1 (en) * 2015-02-12 2016-04-05 United Services Automobile Association (Usaa) Toggling biometric authentication
CN105061373B (zh) * 2015-09-06 2017-10-20 合肥华方医药科技有限公司 一种达格列净异构体杂质的合成方法
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN108699098B (zh) * 2016-01-04 2022-01-25 第一药品株式会社 具有稠合苯环的c-葡糖苷衍生物或其药物学可接受的盐、其制备方法以及包含其的药物组合物
CN105770861B (zh) * 2016-04-08 2020-02-28 吴一行 一种用于治疗男性糖尿病患者勃起功能障碍的药物
WO2018207113A1 (en) * 2017-05-09 2018-11-15 Piramal Enterprises Limited A process for the preparation of sglt2 inhibitor and intermediates thereof
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
US20210388016A1 (en) 2018-10-26 2021-12-16 Janssen Pharmaceutica Nv Glucopyranose derivatives useful as sglt2 inhibitors
US20210388015A1 (en) 2018-10-26 2021-12-16 Janssen Pharmaceutica Nv Glucopyranose derivatives useful as sglt2 inhibitors
EP3938039A4 (en) * 2019-03-14 2022-12-14 Increvet, Inc. LINK FOR THE MANAGEMENT OF FELINE DIABETES
WO2021092341A1 (en) * 2019-11-07 2021-05-14 Increvet, Inc. Sodium-glucose linked transporter inhibitors for the management of chronic kidney disease, hypertension, and heart failure in companion animals
US20230365610A1 (en) * 2020-05-15 2023-11-16 Shanghai Zheye Biotechnology Co. Ltd. Aryl Glucoside Derivative
CN111662166A (zh) * 2020-05-28 2020-09-15 吴赣药业（苏州）有限公司 一种5-溴-2-氯-4′-乙氧基二苯甲烷的制备方法
EP4531810A1 (en) 2022-05-25 2025-04-09 Boehringer Ingelheim Vetmedica GmbH Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
CN120857933A (zh) 2023-03-06 2025-10-28 勃林格殷格翰动物保健有限公司 用于递送特别包含一或多种sglt-2抑制剂的液体药物组合物的系统
AU2024277852A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
TW202508593A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防
WO2025056984A1 (en) * 2023-09-12 2025-03-20 Vijayasri Organics Private Limited A novel process for the preparation of bexagliflozin a sglt2 inhibitor and its intermediates thereof
CN117343115A (zh) * 2023-10-18 2024-01-05 宁波工程学院 基于扭转结构特征的酰胺为原料合成糖缀合物的方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499289A (en) 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
US4933438A (en) 1984-02-29 1990-06-12 University Of Florida Brain-specific analogues of centrally acting amines
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
US4924024A (en) 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
US4871721A (en) 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
US5506219A (en) 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
JP3291730B2 (ja) 1991-05-14 2002-06-10 エルニア スノラソン 疲労症候群の治療
IT1250421B (it) 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5712396A (en) 1992-10-28 1998-01-27 Magnin; David R. α-phosphonosulfonate squalene synthetase inhibitors
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
FR2710265B1 (fr) 1993-09-22 1995-10-20 Adir Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs.
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
DE19541260A1 (de) 1995-11-06 1997-05-07 Lohmann Therapie Syst Lts Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
US5962440A (en) 1996-05-09 1999-10-05 Bristol-Myers Squibb Company Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en) 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
CN1277550A (zh) 1997-09-11 2000-12-20 尼科梅德丹麦有限公司 非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6248864B1 (en) 1997-12-31 2001-06-19 Adherex Technologies, Inc. Compounds and methods and modulating tissue permeability
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
US20020009478A1 (en) 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
SE9802864D0 (sv) 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
ATE286725T1 (de) 1998-10-01 2005-01-15 Novartis Pharma Gmbh Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
FR2792527B1 (fr) 1999-04-22 2004-08-13 Ethypharm Lab Prod Ethiques Microgranules de ketoprofene, procede de preparation et compositions pharmaceutiques
US6172081B1 (en) 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
DE19933926A1 (de) 1999-07-20 2001-01-25 Boehringer Ingelheim Pharma Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
CA2383220C (en) 1999-09-02 2009-11-03 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
US6544548B1 (en) 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
CN1896088A (zh) * 1999-10-12 2007-01-17 布里斯托尔-迈尔斯斯奎布公司 C－芳基葡糖苷sglt2抑制剂
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6080736A (en) 1999-10-27 2000-06-27 Janus Pharmaceuticals, Inc. Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
DE19963234A1 (de) 1999-12-27 2002-01-24 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
AU2463701A (en) 1999-12-29 2001-07-09 Nanodelivery, Inc. Drug delivery system exhibiting permeability control
JP3897594B2 (ja) 2000-01-18 2007-03-28 ノバルティス アクチエンゲゼルシャフト ミクロソームトリグリセリド輸送タンパク質およびアポリポタンパク質分泌の阻害剤として有用なカルボキサミド
EP1253925A1 (en) 2000-01-28 2002-11-06 Bristol-Myers Squibb Company Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6432969B1 (en) 2000-06-13 2002-08-13 Novartis Ag N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6482440B2 (en) 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
JP2004536023A (ja) 2000-11-20 2004-12-02 ブリストル−マイヤーズ　スクイブ　カンパニー ａＰ２インヒビターとしてのピリドン誘導体
US6524615B2 (en) 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
KR100388682B1 (ko) * 2001-03-03 2003-06-25 삼성전자주식회사 반도체 메모리 장치의 스토리지 전극층 및 그 형성방법
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
ATE318272T1 (de) 2001-04-11 2006-03-15 Bristol Myers Squibb Co Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
WO2003006023A1 (en) 2001-07-13 2003-01-23 Bristol-Myers Squibb Company Pyrazinone inhibitors of fatty acid binding protein and method
EP1432720A1 (en) 2001-09-05 2004-06-30 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
CA2494179C (en) 2002-08-08 2012-04-24 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
CN100341885C (zh) 2002-08-09 2007-10-10 大正制药株式会社 选择性制备芳基5－硫代－β－D－吡喃己醛糖苷的方法
MXPA05007052A (es) 2003-01-03 2005-08-18 Squibb Bristol Myers Co Metodos para producir c-aril-glucosidos como inhibidores de sglt2.
KR101001848B1 (ko) 2003-03-14 2010-12-17 고토부키 세이야쿠 가부시키가이샤 Ｃ-글리코시드 유도체 또는 이의 염, 및 이를 포함하는 의약 조성물
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
WO2005005235A2 (en) 2003-07-02 2005-01-20 Keith Gilstrap Bicycle wheel bag
CA2549015A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic c-glycosides
ES2649737T5 (es) 2003-08-01 2021-07-07 Mitsubishi Tanabe Pharma Corp Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
EA011515B1 (ru) 2003-08-01 2009-04-28 Янссен Фармацевтика Н.В. Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
ES2322059T3 (es) 2003-08-26 2009-06-16 Boehringer Ingelheim International Gmbh Glucopiranosiloxi-pirazoles, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion.
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
AU2004275845A1 (en) * 2003-09-24 2005-04-07 Bioxell, S.P.A. Methods for treating bladder dysfunction
US7371732B2 (en) 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
DE10361133A1 (de) 2003-12-22 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2557269C (en) 2004-03-04 2012-12-04 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
DE102004012676A1 (de) * 2004-03-16 2005-10-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE102004040168A1 (de) * 2004-08-18 2006-03-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CN103450129B (zh) 2004-03-16 2015-08-12 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
DE102004061145A1 (de) * 2004-12-16 2006-06-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1731524A4 (en) 2004-03-31 2009-05-20 Kissei Pharmaceutical PHENOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE, AND ITS MEDICINAL USE
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
WO2006010557A1 (de) 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2587639A1 (en) 2004-12-16 2006-06-22 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
DE602006009772D1 (de) 2005-02-23 2009-11-26 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2)
US7975805B2 (en) 2005-04-01 2011-07-12 Oil-Rite Corporation Lubrication system
CA2605245A1 (en) 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (en) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
JP5128474B2 (ja) 2005-07-27 2013-01-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル−置換（（ヘテロ）シクロアルキルエチニル−ベンジル）−ベンゼン誘導体、該化合物を含有する薬剤、それらの使用及びそれらの製造方法
ATE484499T1 (de) 2005-08-30 2010-10-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
WO2007028814A1 (en) 2005-09-08 2007-03-15 Boehringer Ingelheim International Gmbh CRYSTALLINE FORMS OF 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
EP2076503B1 (en) 2006-05-19 2013-07-17 Taisho Pharmaceutical Co., Ltd C-phenyl glycitol compound for the treatment of diabetes
PT2187742T (pt) * 2007-08-23 2018-01-04 Theracos Sub Llc Derivados de (2s,3r,4r,5s,6r)-2-(4-cloro-3-benzilfenil)-6-(hidroximetil)tetrahidro-2h-piran-3,4,5-triol para utilização no tratamento da diabetes
PT2324002T (pt) * 2008-08-22 2016-11-09 Theracos Sub Llc Processos para a preparação de inibidores de sglt2

Also Published As

Publication number Publication date
HUE035947T2 (hu) 2018-06-28
TW200914032A (en) 2009-04-01
RS56822B1 (sr) 2018-04-30
RU2497526C2 (ru) 2013-11-10
SG188800A1 (en) 2013-04-30
RU2010110829A (ru) 2011-09-27
ES2654894T3 (es) 2018-02-15
UA99924C2 (en) 2012-10-25
US7838499B2 (en) 2010-11-23
WO2009026537A1 (en) 2009-02-26
EP2187742B1 (en) 2017-10-25
MX2010002027A (es) 2010-03-15
CA2697349A1 (en) 2009-02-26
EP3318562A2 (en) 2018-05-09
NZ583369A (en) 2011-08-26
HRP20180127T1 (hr) 2018-03-09
EP3318562A3 (en) 2018-09-12
AR110796A2 (es) 2019-05-02
US8106021B2 (en) 2012-01-31
CN101790311B (zh) 2014-04-23
BRPI0815708A2 (pt) 2014-09-30
AU2008288770A1 (en) 2009-02-26
TWI434691B (zh) 2014-04-21
LT2187742T (lt) 2018-01-10
CY1119810T1 (el) 2018-06-27
EP2187742A4 (en) 2012-10-03
DK2187742T3 (en) 2018-01-08
PT2187742T (pt) 2018-01-04
JP2010536882A (ja) 2010-12-02
EP2187742A1 (en) 2010-05-26
BRPI0815708B1 (pt) 2019-07-02
AU2008288770A8 (en) 2012-02-23
ZA201001051B (en) 2011-04-28
NO2187742T3 (pl) 2018-03-24
HK1254895A1 (en) 2019-08-02
US8575321B2 (en) 2013-11-05
US20120329732A1 (en) 2012-12-27
US8802637B2 (en) 2014-08-12
SI2187742T1 (en) 2018-02-28
AU2008288770B2 (en) 2014-06-12
CN101790311A (zh) 2010-07-28
IL203915A (en) 2016-04-21
BRPI0815708B8 (pt) 2021-05-25
US20090118201A1 (en) 2009-05-07
AR068016A1 (es) 2009-10-28
CA2697349C (en) 2012-04-24
BRPI0815708A8 (pt) 2019-04-09
KR20100044909A (ko) 2010-04-30
KR101107425B1 (ko) 2012-01-19
US20110207661A1 (en) 2011-08-25
JP4809931B2 (ja) 2011-11-09
US20140031300A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
PL2187742T3 (pl) Pochodne (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylofenylo)-6-(hydroksymetylo) tetrahydro-2h-pirano-3,4,5-triolu do stosowania w leczeniu cukrzycy
IL210269A0 (en) Solid forms of (2s, 3r,4r, 5s, 6r) - 2 - (4 chloro - 3 (4 - ethoxybenzyl) phenyl) -6 - (methylthio) tetrahydro - 2h - pyran - 3, 4, 5 - triol and methods of their use
IL225672B (en) Pharmaceutical composition comprising (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol for inhibiting rna viral polymerase
SI3133080T1 (sl) Novi citostatski 7-deazapurin nukleozidi
MY166774A (en) L-proline and citric acid co-crystals of (2s,3r,4r,5s,6r)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
PL2661256T3 (pl) Kompozycje zawierające (2S,3R,4R,5S,6R)-2-(4-chloro-3)-(4-etoksybenzylo)fenylo)-6-(metylotio)tetrahydro-2H-pirano-3,4,5-triol
BRPI0917196B8 (pt) forma cristalina de um composto sendo complexo de (2s,3r,4r,5s,6r)- 2- (4- cloro- 3- (4- (2- ciclopropoxietóxi) benzil)fenil)- 6- (hidroximetil) tetraidro- 2h- piran- 3,4,5- triol, bis(l-prolina)
WO2012165914A3 (en) Novel diphenylmethane derivatives as sglt2 inhibitors
WO2011147951A8 (en) Cycloamino derivatives as gpr119 agonists
WO2010147430A3 (en) Novel c-aryl glucoside sglt2 inhibitors and pharmaceutical composition comprising same
PL2376497T3 (pl) Pochodne 5-amino-2-(1-hydroksyetylo)tetrahydropiranu
IL190466A0 (en) Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis
EP1912658A4 (en) THERAPEUTIC PROTOCOLS WITH HYALURONANE
ZA201102796B (en) Novel single unit carbapenem aminoglycoside formulations
WO2012173410A3 (en) Novel c-aryl ansa sglt2 inhibitors
ATE552005T1 (de) Pharmazeutische zusammensetzung hyaluronan als aktive komponente enthaltend
EP1870095A4 (en) COMPOSITION FOR INCREASING ANTI-OXIDATION ACTIVITY IN BLOOD
TH122363A (th) รูปแบบที่เป็นของแข็งของ (2s, 3r, 4r, 5s, 6r)-2-(4-คลอโร-3-(4-เอทธอกซีเบนซิล)-ฟีนิล)-6-(เมทธิลไธโอ)เตตราไฮโดร-2-h-ไพราน-3,4,5-ไตรออล และวิธีการของการใช้สิ่งเหล่านี้
HK1149016A (en) Novel cytostatic 7-deazapurine nucleosides
GB0605035D0 (en) Improvements In Or Relating To The Treatment Of Orthopaedic Infections